Kyowa Kirin Stock Plunges 11% as U.S. Medicaid Deal Sparks Revenue Fears

Shares of Japanese pharmaceutical firm Kyowa Kirin (TYO:4151) plunged on Tuesday, erasing the previous day's gains as investor sentiment soured on a drug pricing deal with the U.S. government. The stock closed down 11.1% at ¥2,390, making it the worst performer on the Nikkei 225 index.

Reversal on U.S. Pricing Deal

The sharp sell-off marked a dramatic reversal from September 1, when news of an agreement to lower prices for the U.S. Medicaid program initially sent the stock higher. According to a report from Investing.com, the market's focus has since shifted to the deal's potential to erode the company's long-term revenue.

Investors are now concerned that the scope of the pricing arrangement, which could expand to more companies and products, may lead to mandatory discounts. This could materially harm Kyowa Kirin's North American operations, a key growth engine for the firm.

Market Pressure and Analyst Outlook

Ad

The stock's decline was exacerbated by a wider market downturn and an already cautious analyst community. The negative sentiment was reflected in the day's trading:

• The stock opened at ¥2,611 before falling to an intraday low of ¥2,360.
• The move showed traders rapidly unwinding bullish positions taken after the deal was first announced.

According to the report, a majority of sell-side analysts covering Kyowa Kirin already held "Sell" or "Underweight" ratings, providing little institutional support to cushion the fall. The broader market provided no relief, as Japan's Nikkei 225 index slid 2.7% during the session.